We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

138 hedge funds and large institutions have $1.31B invested in Clovis Oncology, Inc. in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

26% more call options, than puts

Call options by funds: $31M | Put options by funds: $24.6M

13% more capital invested

Capital invested by funds: $1.16B → $1.31B (+$147M)

8% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 25

1% less funds holding

Funds holding: 140138 (-2)

Holders
138
Holders Change
-2
Holders Change %
-1.43%
% of All Funds
4%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.2%
New
23
Increased
58
Reduced
38
Closed
25
Calls
$31M
Puts
$24.6M
Net Calls
+$6.38M
Net Calls Change
+$17.3M
Name Holding Trade Value Shares
Change
Change in
Stake
CCMH
126
Cornerstone Capital Management Holdings
New York
$36K +$33.4K +800 New
BlackRock
127
BlackRock
New York
$34K
FAM
128
Fred Alger Management
New York
$27K
PAM
129
Panagora Asset Management
Massachusetts
$22K
MAA
130
Managed Account Advisors
New Jersey
$21K +$42 +1 +0.2%
ClearBridge Investments
131
ClearBridge Investments
New York
$11K
LTFS
132
Ladenburg Thalmann Financial Services
Florida
$10K -$210K -5,015 -96%
SGC
133
South Georgia Capital
Illinois
$9K -$4.18K -100 -33%
ATC
134
Adirondack Trust Company
New York
$9K +$2.09K +50 +32%
TRCT
135
Tower Research Capital (TRC)
New York
$4K -$7.52K -180 -65%
EFSCE
136
Enterprise Financial Services Corp (EFSC)
Missouri
$4K +$376 +9 +12%
JG
137
Jefferies Group
New York
$1K +$1.17K +28 New
Manulife (Manufacturers Life Insurance)
138
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$738 +$10.7K +256 +2%
BBA
139
Baker Bros. Advisors
New York
-$32.8M -793,221 Closed
Franklin Resources
140
Franklin Resources
California
-$19.3M -465,198 Closed
SAM
141
Sectoral Asset Management
Quebec, Canada
-$13M -314,952 Closed
JHIU
142
Janus Henderson Investors US
Colorado
-$11.1M -268,977 Closed
QF
143
QVT Financial
New York
-$8.69M -209,735 Closed
Lord, Abbett & Co
144
Lord, Abbett & Co
New Jersey
-$5.1M -123,153 Closed
BNP Paribas Asset Management
145
BNP Paribas Asset Management
France
-$3.78M -91,249 Closed
Capital Fund Management (CFM)
146
Capital Fund Management (CFM)
France
-$3.09M -74,635 Closed
PC
147
PointState Capital
New York
-$2.07M -50,000 Closed
PP
148
Paloma Partners
Connecticut
-$1.45M -35,000 Closed
PAMU
149
Pictet Asset Management (UK)
United Kingdom
-$1.16M -27,900 Closed
SM
150
Sabby Management
Florida
-$828K -20,000 Closed

CLVS Hedge Fund Activity: Q3 2014 in Review

138 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2014, worth a combined $1.31B — up 13% from $1.16B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CLVS and 23 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 58 added.

The largest buyer was PFM Health Sciences, adding an estimated $34.5M. The largest seller was Fidelity Investments, cutting an estimated $46.5M.

  • 138 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2014, down from 140 in Q2 2014.
  • Funds reported $1.31B of Clovis Oncology, Inc. stock for Q3 2014, up 13% quarter-over-quarter.
  • 23 funds opened new Clovis Oncology, Inc. positions in Q3 2014 and 25 closed out, a net change of -2 holders.
  • The largest Clovis Oncology, Inc. buyer in Q3 2014 was PFM Health Sciences, an estimated $34.5M added.
  • The largest Clovis Oncology, Inc. seller in Q3 2014 was Fidelity Investments, an estimated $46.5M sold.

Based on aggregated 13F filings for Q3 2014.